BridgeBio Pharma’s acoramidis demonstrated significant reductions in all-cause mortality and recurrent cardiovascular-related hospitalizations in patients with ATTR-CM, a debilitating heart condition. The positive results from the Phase 3 ATTRibute-CM study highlight the potential of acoramidis as a first-line therapy for ATTR-CM, offering hope for improved quality of life for patients.
Windtree Therapeutics announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients with early cardiogenic shock. The study demonstrated significant improvement in systolic blood pressure and other key parameters, highlighting istaroxime’s potential as a treatment for this critical condition.
The European Medicines Agency (EMA) has recommended a label update for Novo Nordisk’s Wegovy (semaglutide 2.4 mg), incorporating data showing its potential to reduce heart failure symptoms and improve physical function in obese individuals with heart failure with preserved ejection fraction (HFpEF). This update is based on positive results from the STEP HFpEF trials, which demonstrated Wegovy’s efficacy in reducing heart failure symptoms, improving physical limitations, and promoting weight loss compared to placebo.
The global heart failure monitoring systems market is projected to reach a valuation of US$ 14,079.6 million in 2024 and is expected to grow at a CAGR of 5.7% during the forecast period of (2024 to 2034). This growth is fueled by the rising prevalence of cardiovascular diseases and the development of innovative devices for heart and blood vessel management.
Cytokinetics, Incorporated (CYTK) announced positive data from the Phase 1 study of its drug candidate CK-586, a cardiac myosin inhibitor being developed for heart failure with preserved ejection fraction (HFpEF). The study demonstrated safety, tolerability, and favorable pharmacokinetic properties, paving the way for potential once-daily fixed-dose administration in future clinical trials.
Windtree Therapeutics, Inc. (WINT) is seeing its stock rise after completing enrollment in its SEISMiC Extension Phase 2b study of istaroxime for early cardiogenic shock. This study builds upon positive results from a previous trial, focusing on longer dosing duration and exploring potential benefits of a tapering dosage regimen.
This story recounts the emotional rollercoaster a father experiences while battling for his son’s life, navigating heart failure, multiple hospitalizations, and the agonizing wait for a heart transplant. It highlights the strength and resilience of families facing life-altering challenges, offering hope and raising awareness about the critical role of organizations like Great Ormond Street Hospital.
A new study published in The Lancet suggests that semaglutide, a drug commonly used for diabetes and weight loss, may significantly reduce the risk of cardiovascular death and worsening heart failure in patients with specific types of heart failure. The analysis, combining data from four clinical trials, found a 31% reduction in combined cardiovascular death or worsening heart failure events in those taking semaglutide.
In a groundbreaking medical advancement, a 54-year-old grandmother named Lisa Pisano has successfully received the first-ever combined transplant of a gene-edited pig kidney and a mechanical heart pump. The innovative procedure, performed by surgeons at NYU Langone Health, offers hope to individuals facing end-stage organ failure and a shortage of human organ donations. Pisano, who suffers from both end-stage kidney disease and heart failure, was not a candidate for a traditional heart and kidney transplant due to her complex medical conditions. However, the combined pig kidney and heart pump transplant has provided her with a new lease on life.
Doctors at NYU Langone Health have performed a groundbreaking surgery, transplanting a pig kidney into a patient who was near death. The patient, Lisa Pisano, also received a mechanical heart pump to stabilize her failing heart. Pisano is the second patient ever to receive a pig kidney, following a similar transplant at Massachusetts General Hospital last month. This latest surgery marks a significant step forward in the effort to make animal-to-human transplantation a reality.
